Needham analyst Ami Fadia has maintained a Buy rating on Biogen (NASDAQ: BIIB) while raising the stock's price target to $256 from $255 following a meeting with company management. The adjustment reflects continued confidence in the company's performance, driven by positive uptake in its key products and strategic acquisitions. The revised target represents a $1 increase from the prior valuation ceiling.

Product Performance and Strategy

Fadia noted that Spinraza HD uptake has been "quite positive," with demand matching Spinraza’s launch levels. This growth is driven by both new and returning patients. The analyst also highlighted Biogen's progress across in-market products, late-stage assets, and business development, including the recent RayThera acquisition.

Regarding the Alzheimer’s drug Leqembi, Fadia pointed out that predicting the impact of the new under-the-skin (SC) injection on patient numbers is difficult due to frequent switching between injections and IV drips. Many patients prefer clinic-based IV treatments due to a lack of caregivers at home. While more doctors are utilizing blood tests for diagnosis, traditional PET brain scans remain prevalent. The use of blood tests is expected to accelerate patient enrollment in the AHEAD 3-45 clinical study.

Strategic Collaborations and Pipeline

On the Apellis front, management identified a potential collaboration opportunity with Syfovre to expand commercial capabilities for both companies. However, Biogen remains in a learning phase with Empaveli due to limited nephrology experience. Fadia also mentioned that full data for Phase 2 CELIA, expected at the AAIC, should clarify the rationale for advancing diranersen to the registrational stage.

Analyst Metrics

The table below summarizes the updated analyst metrics for Biogen.

Shares of Biogen had risen by 1.05% to $218.29 at the time of publication on Monday.

Biogen Inc. will present new data across its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference (AAIC) 2026, taking place July 12-15 in London, UK. The presentations will include data from the Phase 2 CELIA study evaluating diranersen, an investigational tau-targeting antisense oligonucleotide (ASO), and new analyses from studies of LEQEMBI (lecanemab). The company aims to underscore its leadership in Alzheimer’s care by highlighting advances in treatment delivery, real-world evidence, and approaches targeting core pathologies such as amyloid and tau.

Priya Singhal, M.D., M.P.H., Executive Vice President and Head of Development at Biogen, emphasized the significance of the data. "Tau has long remained one of the most important targets in Alzheimer’s disease, and the Phase 2 CELIA topline results for diranersen reinforce the potential of tau reduction as a therapeutic approach in early Alzheimer’s disease," Singhal said.

Diranersen and CELIA Study Data

The featured presentation on diranersen will include clinical, biomarker, and safety data from the CELIA study. This 18-month Phase 2 randomized, double-blind, placebo-controlled, dose-ranging study evaluated the efficacy, safety, and tolerability of diranersen in individuals with early Alzheimer’s disease. The study enrolled 416 participants with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia, none of whom had previously received anti-amyloid therapy.

Diranersen is an investigational ASO designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. In 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to diranersen for the treatment of Alzheimer’s disease. Biogen obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize diranersen from Ionis Pharmaceuticals in December 2019.

Lecanemab Presentations

Presentations on lecanemab will focus on subcutaneous administration and real-world use. Key sessions include emerging clinical evidence on the subcutaneous formulation and practical use considerations, such as at-home administration. Additionally, the LEADER study will provide three-year real-world evidence from diverse U.S. clinical settings, covering maintenance dosing and patient satisfaction.

LEQEMBI is a humanized monoclonal antibody directed against aggregated soluble protofibril and insoluble forms of amyloid beta. It is indicated in the U.S. for the treatment of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia. The FDA granted traditional approval on July 6, 2023. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both companies co-commercializing the product.